Tranexamic Acid for Recovery After Modified Radical Mastoidectomy in Patients With Chronic Suppurative Otitis Media
Clinical Study on the Application of Tranexamic Acid to Improve the Prognosis of Surgical Treatment for Chronic Suppurative Otitis Media
The main objective of this project is to conduct a multicentre, prospective, randomised, controlled clinical trial to evaluate the clinical value of tranexamic acid in patients undergoing mastoidectomy. The study population consists of patients with chronic suppurative otitis media scheduled to undergo mastoidectomy. They will be randomised in a 1:1 ratio to either the pre-operative intravenous tranexamic acid group or the saline control group; both groups will undergo treatment in accordance with standardised anaesthesia and surgical protocols. The main research components include:
- Evaluation of the dry ear rate: The primary outcome measure was to compare the difference in dry ear rates between the two groups one month post-operatively, in order to verify the effect of tranexamic acid on improving the dry ear rate following mastoidectomy. The assessment of the dry ear rate was carried out by an ENT specialist unaware of the study group allocation via clinical otoscopic examination; a dry ear was defined as the absence of discharge in the ear canal and complete epithelialisation of the mastoid surgical site. The assessment time point for the primary outcome measure was one month post-operatively.
- Postoperative hearing assessment: This will be assessed based on the improvement in hearing at 3 months postoperatively compared with preoperative levels.
- Safety assessment: The safety assessment will primarily include common adverse reactions associated with the use of tranexamic acid (e.g. nausea, vomiting, dizziness) and serious adverse events (e.g. venous thromboembolism, myocardial infarction, epileptic seizures). These will be comprehensively evaluated in conjunction with clinical signs and laboratory tests to ensure the safety and feasibility of the intervention.
Through this study, the project aims to determine whether tranexamic acid can effectively reduce the incidence of dry ear in the early postoperative period following mastoidectomy, and to provide evidence-based support for its clinical implementation.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 4
連絡先と場所
研究連絡先
研究連絡先
- 名前:Haiyan An, MD,PhD
- 電話番号:+86 135 2155 3036
- メール:anhaiyan76@163.com
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100034
- Peking University First Hospital
-
コンタクト:
- DongLiang Mu, MD,PhD
- 電話番号:+86 17810370608
- メール:mudongliang@bjmu.edu.cn
-
Beijing、Beijing Municipality、中国、100044
- Peking University People's Hospital
-
コンタクト:
- Haiyan An, MD,PhD
- 電話番号:+86 135 2155 3036
- メール:anhaiyan76@163.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18-65 years, regardless of sex
- American Society of Anesthesiologists (ASA) physical status I-II
- Patients diagnosed with chronic suppurative otitis media (CSOM) who have had an inadequate response to conservative medical treatment
- Patients scheduled to undergo microscopic open (canal wall-down) radical mastoidectomy
- Patients who provide written informed consent
Exclusion Criteria:
- Known allergy or hypersensitivity to tranexamic acid (TXA)
- Severe hepatic or renal disease (hepatic or renal decompensation); thromboembolic diseases, including deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction; a history of epilepsy, including seizures induced by any cause; or coagulation disorders (any of the following coagulation parameters-activated partial thromboplastin time [APTT], prothrombin time [PT], fibrinogen [FIB], or D-dimer [D-D]-exceeding 1.5 times the upper limit of the normal range)
- Use of anticoagulant or antiplatelet medications within 2 weeks before surgery, including aspirin, clopidogrel, warfarin, or other such medications
- Color blindness, pregnancy, or breastfeeding
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター:Normal Saline (NS) Group
An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision. |
An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision. |
|
実験的:Tranexamic Acid (TXA) Group
Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision. |
Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dry ear rate
時間枠:1 month (±1 week) after surgery
|
A dry ear is defined as no exudate in the external auditory canal or mastoid cavity and complete epithelialization of the surgical cavity. Dry ear status will be assessed by an otolaryngologist using otoendoscopy. |
1 month (±1 week) after surgery
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Hearing improvement
時間枠:3 months after surgery (±2 weeks)
|
Pure-tone audiometry will be used to assess hearing thresholds at 0.5, 1, 2, and 4 kHz. Air-conduction (AC), bone-conduction (BC), and air-bone gap (ABG) thresholds will be recorded at each frequency. |
3 months after surgery (±2 weeks)
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and tolerability
時間枠:At postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks)
|
Adverse events will be assessed at postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks), including common adverse events such as nausea, vomiting, and dizziness, as well as serious adverse events such as arterial or venous thromboembolism, myocardial infarction, and seizures. These assessments will be used to evaluate the safety of preoperative intravenous administration of tranexamic acid in patients undergoing modified radical mastoidectomy. |
At postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks)
|
協力者と研究者
協力者
協力者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 2026PHB663-001
- 首发2026-2-4085 (その他の助成金/資金番号:Beijing Municipal Health Commission)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be shared with other researchers due to patient privacy and confidentiality considerations, as well as institutional data protection requirements. Only aggregated study results may be made publicly available through scientific publications.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。